Compare Baxter International Inc (BAX) vs Expensify Inc (EXFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Expensify Inc — how do they compare? Baxter International Inc trades at $21.78 (market cap $11.26B), while Expensify Inc trades at $1.81 (market cap $175.04M). The key difference: Baxter International Inc is far larger — about 64.3× Expensify Inc's market cap, and Baxter International Inc pays a 0.92% dividend while Expensify Inc pays none. Which is the better fit depends on your goals.
| BAX | EXFY | |
|---|---|---|
Market Cap | $11.26B | $175.04M |
Sector | Health | Technology |
52-Week High | $29.22 | $2.33 |
52-Week Low | $15.80 | $0.75 |
Enterprise Value | $18.93B | $114.07M |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
Expensify (EXFY) trades at $1.79, down 5.29% today, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.04, beating expectations, but maintains negative net income margins. Recent news highlights product launches including AI-powered expense automation and a $25 million stock buyback program. Revenue remains stable around $140 million annually with improving cash flow from operations.
Outlook remains mixed with analyst consensus evenly split between Buy and Hold. Key opportunities include product innovation and cost management, while risks involve persistent profitability challenges and competitive pressure in expense management software. The stock's valuation shows high P/E ratio despite negative earnings, requiring careful fundamental assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →
